Sonoma Pharmaceuticals (SNOA) Net Cash Flow Growth (3y) (2013 - 2026)
Sonoma Pharmaceuticals (SNOA) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.12 Mn | -222,819.83 | 2.58 Mn | 112.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.81% |
| Mar 31, 2026 | -29.85% |
| Dec 31, 2025 | 1.66% |
| Sep 30, 2025 | 31.45% |
| Jun 30, 2025 | -3.90% |
| Mar 31, 2025 | 27.67% |
| Dec 31, 2024 | 110.12% |
| Sep 30, 2024 | -31.97% |
| Jun 30, 2024 | 42.54% |
| Mar 31, 2024 | 38.45% |
| Dec 31, 2023 | -38.26% |
| Sep 30, 2023 | -82.79% |
| Jun 30, 2023 | -34.50% |
| Mar 31, 2023 | 112.08% |
| Dec 31, 2022 | -49.85% |
| Sep 30, 2022 | -27.46% |
| Jun 30, 2022 | -74.28% |
| Mar 31, 2022 | 24.21% |
| Dec 31, 2021 | -62.04% |
| Sep 30, 2021 | 51.86% |